Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES A TUMLIN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1467418053
CMS profile
156467
Location
LAWRENCEVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$49,854.48

80 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES A TUMLIN

NPI 1467418053 · CMS profile ID 156467

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LAWRENCEVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES A TUMLIN, NPI 1467418053, CMS profile ID 156467. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JAMES A TUMLIN, NPI 1467418053, CMS profile ID 156467. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JAMES A TUMLIN, NPI 1467418053, CMS profile ID 156467, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467418053?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

80 matching records · $49,854.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 80 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–80 of 80.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Travere Therapeutics, Inc. $27.9604/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919322 CMS
CALLIDITAS THERAPEUTICS US INC. $104.2604/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141513245 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5404/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118020004 CMS
AstraZeneca Pharmaceuticals LP $80.3504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105878727 CMS
CALLIDITAS THERAPEUTICS US INC. $15.6603/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512345 CMS
Aurinia Pharma U.S., Inc. $150.0003/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150693667 CMS
CALLIDITAS THERAPEUTICS US INC. $145.0003/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512183 CMS
CALLIDITAS THERAPEUTICS US INC. $121.1203/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512145 CMS
CALLIDITAS THERAPEUTICS US INC. $79.9603/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512147 CMS
CALLIDITAS THERAPEUTICS US INC. $79.9603/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512149 CMS
CALLIDITAS THERAPEUTICS US INC. $79.9603/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512151 CMS
CALLIDITAS THERAPEUTICS US INC. $79.9603/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512153 CMS
CALLIDITAS THERAPEUTICS US INC. $179.6403/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141512155 CMS
CALLIDITAS THERAPEUTICS US INC. $74.5603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511899 CMS
CALLIDITAS THERAPEUTICS US INC. $51.1803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511901 CMS
CALLIDITAS THERAPEUTICS US INC. $165.0003/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511903 CMS
CALLIDITAS THERAPEUTICS US INC. $310.9403/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511905 CMS
CALLIDITAS THERAPEUTICS US INC. $489.2003/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511731 CMS
Alnylam Pharmaceuticals Inc. $21.9303/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125822509 CMS
CALLIDITAS THERAPEUTICS US INC. $48.4403/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141511285 CMS
Travere Therapeutics, Inc. $506.1502/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919337 CMS
Travere Therapeutics, Inc. $2,000.0002/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919356 CMS
Travere Therapeutics, Inc. $177.2601/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919329 CMS
Travere Therapeutics, Inc. $1,106.7101/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919352 CMS
Travere Therapeutics, Inc. $22.7901/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919318 CMS
Travere Therapeutics, Inc. $399.8401/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919333 CMS
Travere Therapeutics, Inc. $3,100.1601/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149919360 CMS
CALLIDITAS THERAPEUTICS US INC. $31.5101/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141507892 CMS
CALLIDITAS THERAPEUTICS US INC. $32.0001/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141507894 CMS
CALLIDITAS THERAPEUTICS US INC. $547.8001/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141507896 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $58,574.56 82
PY2020 $58,025.14 55
PY2021 $63,921.48 95
PY2022 $79,163.81 109
PY2023 $77,992.65 84
PY2024 $49,854.48 80
PY2025 $46,323.95 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,261.27 3
PY2025 Principal investigator $4,834,551.62 45
PY2024 Principal investigator $3,444,563.66 40
PY2023 Principal investigator $5,928,056.97 58
PY2022 Principal investigator $3,057,107.35 103
PY2021 Principal investigator $761,619.26 169
PY2020 Recipient $18,821.80 4
PY2020 Principal investigator $705,471.69 163
PY2019 Principal investigator $592,888.85 247

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $25,228.00 12/29/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675764
Principal investigator 1 CSL Behring $849.68 12/18/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668562
Principal investigator 1 Humacyte Global, Inc. $16,091.00 12/01/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959485
Principal investigator 1 Humacyte Global, Inc. $15,841.15 12/01/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959489
Principal investigator 1 Genentech, Inc. $9,675.00 11/21/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211610839
Principal investigator 1 CSL Behring $116.77 10/29/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668560
Principal investigator 1 Genentech, Inc. $23,430.71 10/28/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211610834
Principal investigator 1 Humacyte Global, Inc. $4,722.73 10/09/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959481
Principal investigator 1 Humacyte Global, Inc. $28,980.02 10/08/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959341
Principal investigator 1 Humacyte Global, Inc. $22,841.23 10/08/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959483
Principal investigator 1 CSL Behring $94.69 10/07/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668558
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $18,002.58 09/26/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy No dispute reported 06/30/2026 1214124086
Principal investigator 1 Novartis Pharmaceuticals Corporation $634,216.41 09/15/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy No dispute reported 06/30/2026 1190310534
Principal investigator 1 CSL Behring $90.79 09/10/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668556
Principal investigator 1 CSL Behring $548.15 09/08/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668554
Principal investigator 1 Alexion Pharmaceuticals, Inc. $16,498.44 09/04/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY, LLC
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185551719
Principal investigator 1 Genentech, Inc. $3,046.00 08/27/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211610830
Principal investigator 1 Humacyte Global, Inc. $16,557.74 08/25/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959487
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,500.00 08/19/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy No dispute reported 06/30/2026 1190310538
Principal investigator 1 CSL Behring $16.71 08/11/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668552
Principal investigator 1 CSL Behring $250.38 07/22/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668550
Principal investigator 1 Alexion Pharmaceuticals, Inc. $32,090.05 07/18/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY
a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN No dispute reported 06/30/2026 1185551711
Principal investigator 1 Genentech, Inc. $1,018.00 07/11/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211610825
Principal investigator 1 Humacyte Global, Inc. $5,200.68 07/02/2025 Non-covered Recipient Entity
NephroNet CRO LLC
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis No dispute reported 06/30/2026 1254959479
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,000.00 07/01/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy No dispute reported 06/30/2026 1190311549
Principal investigator 1 CSL Behring $1,085.91 06/13/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668548
Principal investigator 1 Mallinckrodt Hospital Products Inc. $170,700.00 04/30/2025 Non-covered Recipient Entity
NEPHRONET INC
COMPARATIVE SAFETY AND EFFICACY OF ACTHAR GEL ALONE OR IN COMBINATION WITH ORAL TACROLIMUS TO REDUCING PROTEINURIA IN PATIENTS WITH IDIOPATHIC FIBRILLARY GLOMERULOPATHY No dispute reported 06/30/2026 1212110460
Principal investigator 1 Novartis Pharmaceuticals Corporation $149,982.69 04/04/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190310528
Principal investigator 1 Genentech, Inc. $12,979.00 04/01/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211610822
Recipient F. Hoffmann-La Roche AG $2,271.59 03/31/2025 Covered Recipient Physician Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211536255
Recipient F. Hoffmann-La Roche AG $234.86 03/31/2025 Covered Recipient Physician Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211536259
Recipient F. Hoffmann-La Roche AG $754.82 03/31/2025 Covered Recipient Physician Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211536264
Principal investigator 1 AstraZeneca Pharmaceuticals LP $317,811.81 03/20/2025 Non-covered Recipient Entity
NEPHRONET
A ProsPective Open-Labeled Study of Anifrolumab in the Treatment of Collapsing Variant and APOL-1 Positive FSGS PROPOSAL Study No dispute reported 06/30/2026 1185551714
Principal investigator 1 CSL Behring $1,850.36 03/05/2025 Non-covered Recipient Entity
Georgia Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252668546
Principal investigator 1 AstraZeneca Pharmaceuticals LP $373,377.20 03/04/2025 Non-covered Recipient Entity
NEPHRONET
A ProsPective Open-Labeled Study of Anifrolumab in the Treatment of Collapsing Variant and APOL-1 Positive FSGS PROPOSAL Study No dispute reported 06/30/2026 1185551717
Principal investigator 1 Travere Therapeutics, Inc. $1,436.40 03/03/2025 Non-covered Recipient Entity
Georgia Nephrology LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183717
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,650.60 02/27/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy No dispute reported 06/30/2026 1190311547
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $152,482.17 02/25/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease No dispute reported 06/30/2026 1214125226
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,282,747.36 02/24/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care No dispute reported 06/30/2026 1190310532
Principal investigator 1 Novartis Pharmaceuticals Corporation $791,454.90 02/17/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy No dispute reported 06/30/2026 1190310536
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $107,768.60 01/28/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) No dispute reported 06/30/2026 1214124088
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $5,604.05 01/23/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY No dispute reported 06/30/2026 1225335379
Principal investigator 1 Genentech, Inc. $10,842.00 01/22/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211610818
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,867.80 01/22/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190310530
Principal investigator 1 Novartis Pharmaceuticals Corporation $141.60 01/15/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY RESEARCH INSTITUTE
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy No dispute reported 06/30/2026 1190310540
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $230,446.46 01/11/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LAWRENCEVILLE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124960
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $32,488.85 01/03/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LLC
A PHASE 2/3, MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY No dispute reported 06/30/2026 1225335175
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $267,926.95 01/01/2025 Non-covered Recipient Entity
GEORGIA NEPHROLOGY LAWRENCEVILLE BILLING OFFICE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214124962